Esketamine

Brand names: Spravato · Active ingredient: Esketamine Hydrochloride

In short: SPRAVATO is indicated for the treatment of: Treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressa

Forms & strengthsNasal Spray: 28 mg of esketamine per device. Each nasal spray device delivers two sprays containing a total of 28 mg esketamine.
LabelJanssen Pharmaceuticals, Inc.
Label updatedSep 24, 2026

What is Esketamine used for?

SPRAVATO is indicated for the treatment of:

Treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant

Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant

Limitations of Use

The effectiveness of SPRAVATO in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated

. Use of SPRAVATO does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO.

SPRAVATO is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO as an anesthetic agent have not been established.

âš  Boxed warning (FDA's strongest warning)

Sedation

Patients are at risk for sedation after administration of SPRAVATO

.

Dissociation

Patients are at risk for dissociative or perceptual changes after administration of SPRAVATO

.

Respiratory Depression

Respiratory depression has been observed in postmarketing experience

.

Because of the risks of sedation, dissociation, and respiratory depression, patients must be monitored for at least 2 hours at each treatment session, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting

.

Abuse and Misuse

SPRAVATO has the potential to be abused and misused. Consider the risks and benefits of prescribing SPRAVATO prior to use in patients at higher risk of abuse. Monitor patients for signs and symptoms of abuse and misuse

.

Because of the risks of serious adverse outcomes resulting from sedation, dissociation, respiratory depression, abuse and misuse, SPRAVATO is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the SPRAVATO REMS

.

Suicidal Thoughts and Behaviors

Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. SPRAVATO is not approved for use in pediatric patients

.

Esketamine dosage

SPRAVATO must be administered under the direct supervision of a healthcare provider. A treatment session consists of nasal administration of SPRAVATO and post-administration observation under supervision.

Respiratory Status Assessment During Treatment

Monitor patients for changes in respiratory status for at least 2 hours (including pulse oximetry) at each treatment session

.

Blood Pressure Assessment Before and After Treatment

Assess blood pressure prior to dosing with SPRAVATO

.

If baseline blood pressure is elevated (e.g., >140 mmHg systolic, >90 mmHg diastolic), consider the risks of short term increases in blood pressure and benefit of SPRAVATO treatment

.

Do not administer SPRAVATO if an increase in blood pressure or intracranial pressure poses a serious risk

.

After dosing with SPRAVATO, reassess blood pressure at approximately 40 minutes (which corresponds with the Cmax) and subsequently as clinically warranted.

If blood pressure is decreasing and the patient appears clinically stable for at least two hours, the patient may be discharged at the end of the post-dose monitoring period; if not, continue to monitor

.

Food and Liquid Intake Recommendations Prior to Administration

Because some patients may experience nausea and vomiting after administration of SPRAVATO

,

advise patients to avoid food for at least 2 hours before administration and to avoid drinking liquids at least 30 minutes prior to administration.

Nasal Corticosteroid or Nasal Decongestant

Patients who require a nasal corticosteroid or nasal decongestant on a dosing day should administer these medications at least 1 hour before SPRAVATO

.

The recommended dosage of SPRAVATO for the treatment of TRD in adults as monotherapy or in conjunction with an oral antidepressant is shown in Table 1. Dosage adjustments should be made based on efficacy and tolerability. Evidence of therapeutic benefit should be evaluated at the end of the induction phase to determine need for continued treatment.

Adults

Induction Phase | Weeks 1 to 4:

Administer twice per week | 56 mg or 84 mg

Maintenance Phase | Weeks 5 to 8

:

Administer once weekly | 56 mg or 84 mg

Week 9 and after

:

Administer every 2 weeks or once weeklyDosing frequency should be individualized to the least frequent dosing to maintain remission/response. | 56 mg or 84 mg

Administer SPRAVATO in conjunction with an oral antidepressant (AD).

The recommended dosage of SPRAVATO for the treatment of depressive symptoms in adults with MDD with acute suicidal ideation or behavior is 84 mg twice per week for 4 weeks. Dosage may be reduced to 56 mg twice per week based on tolerability. After 4 weeks of treatment with SPRAVATO, evidence of therapeutic benefit should be evaluated to determine need for continued treatment. …

How to take Esketamine — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Sedation, Dissociation, and Respiratory Depression

Inform patients that SPRAVATO has potential to cause sedation, dissociative symptoms (including perception disturbances), dizziness, vertigo, anxiety, and respiratory depression. Advise patients that they will need to be observed by a healthcare provider until these effects resolve

.

Potential for Abuse, Misuse, and Dependence

Advise patients that SPRAVATO is a federally controlled substance because it can be abused or lead to dependence

.

SPRAVATO Risk Evaluation and Mitigation Strategy (REMS)

SPRAVATO is available only through a restricted program called the SPRAVATO REMS

. Inform the patient of the following notable requirements:

Patients treated in outpatient healthcare settings (e.g. medical offices and clinics) must be enrolled in the SPRAVATO REMS Program prior to administration.

SPRAVATO must be administered under the direct observation of a healthcare provider.

Patients must be monitored by a healthcare provider for at least 2 hours after administration of SPRAVATO. …

Warnings & precautions

Do not take this medicine if: SPRAVATO is contraindicated in patients with:

Aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels) or arteriovenous malformation

History of intracerebral hemorrhage

Hypersensitivity to esketamine, ketamine, or any of the excipients.

SPRAVATO may cause sedation or loss of consciousness. In some cases, patients may display diminished or less apparent breathing. In clinical trials, 48% to 61% of SPRAVATO-treated patients developed sedation based on the Modified Observer's Assessment of Alertness/Sedation scale (MOAA/S)

, and 0.3% to 0.4% of SPRAVATO-treated patients experienced loss of consciousness (MOAA/S score of 0).

Because of the possibility of delayed or prolonged sedation, patients must be monitored by a healthcare provider for at least 2 hours at each treatment session, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting

.

Closely monitor for sedation with concomitant use of SPRAVATO with CNS depressants

.

SPRAVATO is available only through a restricted program under a REMS

.

The most common psychological effects of SPRAVATO were dissociative or perceptual changes (including distortion of time, space and illusions), derealization and depersonalization (61% to 84% of SPRAVATO-treated patients developed dissociative or perceptual changes based on the Clinician-Administered Dissociative States Scale)

. Given its potential to induce dissociative effects, carefully assess patients with psychosis before administering SPRAVATO; treatment should be initiated only if the benefit outweighs the risk. …

Esketamine side effects

The following adverse reactions are discussed in more detail in other sections of the labeling:

Sedation

Dissociation

Respiratory Depression

Increase in Blood Pressure

Cognitive Impairment

Impaired Ability to Drive and Operate Machinery

Ulcerative or Interstitial Cystitis

Embryo-fetal Toxicity

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Treatment-Resistant Depression

In Conjunction with an Oral Antidepressant

SPRAVATO was evaluated for safety in 1709 adults diagnosed with treatment-resistant depression (TRD)

from five Phase 3 studies (3 short-term and 2 long-term studies) and one Phase 2 dose-ranging study. Of all SPRAVATO-treated patients in the completed Phase 3 studies, 479 (30%) received at least 6 months of treatment, and 178 (11%) received at least 12 months of treatment.

Adverse Reactions Leading to Discontinuation of Treatment

In short-term studies in adults <65 years old (Study 1 pooled with another 4-week study), the proportion of patients who discontinued treatment because of an adverse reaction was 4.6% in patients who received SPRAVATO plus oral AD compared to 1.4% for patients who received placebo nasal spray plus oral AD. For adults ≥65 years old, the proportions were 5.6% and 3.1%, respectively. …

Drug interactions

Concomitant use with CNS depressants (e.g., benzodiazepines, opioids, alcohol) may increase sedation

. Closely monitor for sedation with concomitant use of SPRAVATO with CNS depressants.

Concomitant use with psychostimulants (e.g., amphetamines, methylphenidate, modafinil, armodafinil) may increase blood pressure

. Closely monitor blood pressure with concomitant use of SPRAVATO with psychostimulants.

Concomitant use with monoamine oxidase inhibitors (MAOIs) may increase blood pressure

. Closely monitor blood pressure with concomitant use of SPRAVATO with MAOIs.

About this medicine

SPRAVATO

®contains esketamine hydrochloride, a non-competitive

N-methyl-

D-aspartate (NMDA) receptor antagonist. Esketamine is the S-enantiomer of racemic ketamine. The chemical name is

(S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride. Its molecular formula is C13H16ClNO.HCl and its molecular weight is 274.2. The structural formula is:

Esketamine hydrochloride is a white or almost white crystalline powder that is freely soluble in water and in methanol, and soluble in ethanol.

SPRAVATO nasal spray is intended for nasal administration. Esketamine hydrochloride is contained as a solution in a stoppered glass vial within the nasal spray device. Each device delivers two sprays with a total of 32.3 mg of esketamine hydrochloride (equivalent to 28 mg of esketamine) in 0.2 mL of a clear, colorless aqueous solution with a pH of 4.5.

The inactive ingredients are citric acid monohydrate, edetate disodium, sodium hydroxide, and water for injection. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d81a6a79-a74a-44b7-822c-0dfa3036eaed. Read the full official label on DailyMed.

Related medicines

Sertraline Escitalopram Bupropion Fluoxetine Trazodone Duloxetine Prednisone Buspirone